Background: Prognostic markers for risk stratification of patients with gastrointestinal high-grade neuroendocrine carcinomas (GI-NECs) are lacking; we designed and validated a prognostic score for overall survival (OS). Methods: Consecutive patients diagnosed in five neuroendocrine specialist European centers were included. Patients were divided into three cohorts: a training cohort (TC), an external validation cohort (EVC), and a prospective validation cohort (PVC). Prognostic factors were identified by log-rank test, Cox-regression, and logistic regression analyses. The derived score was internally and externally validated. All statistical tests were two-sided. Results: Of 395 patients screened, 313 were eligible (TC ¼ 109 patients, EVC ¼ 184 patients, and PVC ¼ 20 patients). The derived prognostic score included five variables: presence of liver metastases, alkaline phosphatase (ALK), lactate dehydrogenase (LDH), Eastern Cooperative Oncology Group performance status (ECOG PS), and Ki67. In multivariable analysis, the score was prognostic for OS (hazard ratio [HR] ¼ 1.86, 95% confidence interval [CI] ¼ 1.47 to 2.35, P < .001) and had good discrimination (C-index ¼ 0.76) and calibration (mean error ¼ 0.021, 90th percentile ¼ 0.037) in the TC. These results were validated in the EVC and PVC, in which our score was able to prognosticate for OS when adjusted for other prognostic variables in the multivariable analysis (HR ¼ 1.85, 95% CI ¼ 1.27 to 2.71, P ¼ .001; and HR ¼ 4.51, 95% CI ¼ 1.87 to 10.87, P ¼ .001, respectively). The score classified patients into two groups with incremental risk of death: group A (0-2 points, 181 patients [63.9%], median OS ¼ 19.4 months, 95% CI ¼ 16.1 to 25.1) and group B (3-6 points, 102 patients [36.1%], median OS ¼ 5.2 months, 95% CI ¼ 3.6 to 6.9). Conclusions: The GI-NEC score identifies two distinct patient cohorts; it provides a tool for clinicians when making treatment decisions and may be used as a stratification factor in future clinical trials.
Neuroendocrine malignancies from the gastrointestinal (GI) tract are relatively rare, although the incidence has been rising during recent years (1) . Because of the impact on treatment strategy and survival, patients with neuroendocrine malignancies are classified according to both tumor morphology and assessment of proliferation according to World Health Organization (WHO)/European Neuroendocrine Tumor Society (ENETS) guidelines. Morphology is classed as well-or poorly differentiated; proliferation is assessed objectively by Ki-67 or mitotic count. Malignancies with a Ki-67 index greater than 20% are considered high-grade neuroendocrine carcinomas (NEC-G3) (2) (3) (4) . Well-differentiated tumors with a proliferation index of greater than 20% have recently been described, so-called NET-G3, as a discrete entity with clinical relevance (5, 6) .
Gastrointestinal NECs (GI-NECs) represent only 5% to 10% of all digestive neuroendocrine malignancies (7, 8) and arise mainly from the stomach, pancreas, or colon (9) (10) (11) . They are usually diagnosed in advanced stages, when only palliative treatment is available. In contrast to well-differentiated GINETs (1), the median survival of patients with NECs (all stages) is clinically significantly shorter (estimated to be around 12 to 17 months) because of their aggressive natural history (6, 12) . Distant disease is present at initial diagnosis in 57% of patients and impacts survival: The median survival durations are 38 months (95% confidence interval [CI] ¼ 31 to 45 months), 16 months (95% CI ¼ 15 to 17 months), and five months (95% CI ¼ 4.7 to 5.4 months) for patients with localized, locally advanced, and metastatic disease, respectively (1, 13) .
Management of GI-NECs with advanced disease is based on systemic cytotoxic chemotherapy due to high mitotic activity and rapid rate of disease progression. Current treatments are based on data from small cell lung cancer, such as cisplatin-etoposide or carboplatin-etoposide (14) . Firstline treatment for GI-NECs has remained unchanged since the early 1990s, when high tumor response rates were reported with etoposide-platinum combination (41%-67%) (15) . In addition, a number of small retrospective series have published results of other chemotherapy regimens (temozolomide-based [12, 16] , taxane-based [12] , 5-FU-based [17, 18] , or topotecan [19] ) after failure of platinum-etoposide therapy in patients with NECs (12, (16) (17) (18) (19) (20) . Results from ongoing studies such as the ECOG-ACRIN 2142 trial (NCT02595424), which plans to randomly assign 126 patients diagnosed with NEC-G3 to firstline cisplatin/ etoposide or capecitabine/temozolomide, may clarify the most suitable treatment for this population of patients.
Prognostic factors have been reported in small series but have not been externally validated. These include Ki67 (12), Eastern Cooperative Oncology Group performance status (ECOG-PS) (12, 21) , elevated lactate dehydrogenase (LDH) (12, 21) , primary site (12, 21, 22) , thrombocytosis (12) , and tumor morphology (6) . It is worth highlighting that survival reported between different series vary from 20 months (16, 18, 20) to three months (19) , suggesting marked heterogeneity of the patient populations. In addition, clinicians are lacking tools to identify patients who may have longer survival and therefore may benefit from active treatment or inclusion in clinical trials.
In this study, the aim was to design and validate a score prognostic for overall survival (OS) in patients with GI-NECs.
Methods

Study Design
Three cohorts of patients were analyzed: a training cohort (score was designed and internally validated), an external validation cohort (score was externally validated), and a prospective validation cohort (score was prospectively validated). Approval for data collection was obtained independently by each one of the institutions involved as per local practice.
Patients in Cohort 1: Training Cohort
All consecutive patients diagnosed with GI-NEC between January 1997 and June 2014 at The Christie NHS Foundation Trust (Manchester, UK) were included in this retrospective cohort. Eligible patients where those with a diagnosis of GI-NEC (including patients with an unknown primary in whom the primary tumor was suspected to be of GI origin) with a Ki67 greater than 20% and available survival data. Site of primary tumor was classified as foregut (oesophagus, stomach, and proximal duodenum; excluding pancreas), midgut (distal duodenum, appendix, and proximal colon), pancreas, hindgut (colon and rectum), or unknown primary according to clinical information available. Patients with ECOG-PS 4 and patients with mixed adenoneuroendocrine carcinoma were excluded. Demographic characteristics together with ECOG-PS, stage (23, 24) , primary GI tumor site, sodium, alkaline phosphatase (ALP), LDH, and Ki67 at time of first diagnosis were collected for identification of prognostic factors and design of the prognostic score (25, 26) . The primary end point was OS, defined as the time between first diagnosis of NEC and death (or last follow-up with no death).
Patients in Cohort 2: External Validation Cohort
Patients diagnosed with GI-NECs who were seen between April 2000 and December 2015 were identified retrospectively in five different European Countries (France, Belgium, Germany, Spain, and the UK) from centers with expertise in neuroendocrine malignancies. The same inclusion criteria as the training cohort were used, and the same baseline and demographic characteristics were collected. Patients with missing data in any one of the items included in the score were excluded and considered ineligible. The primary end point was OS. A sample size for external validation was estimated to replicate the hazard ratio achieved by the score (as a discrete variable) in the multivariable analysis from the training cohort (hazard ratio [HR] ¼ 1.9); a minimum of 82 patients was required to externally validate the score (power ¼ 80% and two-tailed a-error ¼ .05).
Patients in Cohort 3: Prospective Validation Cohort
The Prospective Validation Cohort included all consecutive patients diagnosed with GI-NECs seen at The Christie NHS Foundation Trust between July 2014 and November 2015. Patients were identified and data was collected prospectively. The same inclusion criteria and data collection items as in the External Validation Cohort were applied; patients with missing data for any of the score items were excluded. The primary end point was OS.
Description of Baseline Characteristics and Comparison Between Cohorts
The median, with range and/or 95% confidence interval (CI), was calculated for continuous/discrete variables. Percentages were employed for distribution of categorical variables. Chisquare and t tests were used for comparison of baseline ARTICLE characteristics, as appropriate. Comparisons with P values of .05 or less were considered statistically significant.
Statistical Analysis
Statistical analysis was performed with Stata v.12 and R Studio packages. All statistical tests were two-sided.
Design of the Prognostic Score (Training Cohort) Cox regression, Kaplan-Meier, log-rank test, and logistic regression were employed for identification of relevant factors impacting OS. Proportionality of hazards assumption was assessed by graphic methods such as log-log plot of survival and Kaplan-Meier observed/predicted survival plot. A maximum regression model, including all the statistically significant variables in the univariate Cox-regression (defined as P .05) and previously defined "variables of interest" (ECOG-PS, stage, and Ki67), was designed. Treatment-related variables (such as administration of chemotherapy or radiological response) were excluded from the maximum regression model. The prognostic score included selected items from the maximum regression model, which were chosen by the allsets Stata command (selecting the model with lower Akaike information criterion (AIC), lower number of variables, and without duplicated clinical information).
Once the variables to be included in the prognostic score were identified, a score nomogram was built. First, continuous/ discrete variables were categorized, taking into account the most suitable cutoff according to receiver operating characteristic (ROC) analysis for prediction of death-and second, KaplanMeier curve for prediction of OS to confirm the tested cutoff as the most informative one in terms of our primary end point (OS). Finally, the punctuation for each item's category was selected to be proportional to the hazard ratio achieved in the multivariable Cox regression analysis.
Accuracy of Prediction of Risk of Survival: Prognostic Score Compared With the Maximum Regression Model (Training Cohort)
The impact of the score on survival was confirmed by multivariable Cox regression adjusted for other variables with known prognostic impact that were not included in the score. ROC curve comparison test (by comparison of area under the curve [AUC]) was employed to compare the accuracy of prediction of survival at three, six, nine, 12, 18, and 24 months of the maximum model (considered the gold standard) and the prognostic score. Comparisons with P values of .05 or less were considered statistically significant.
Internal Validation of the Prognostic Score (Training Cohort)
Internal validation of the score was performed by bootstrap-corrected Harrell Concordance Index (C-Index) calculation and resampling model calibration. For interpretation of results of the C-Index, an index of 1 was considered to be perfectly discriminating, while a C-Index of 0.5 was as good as a random estimation.
External Validation of the Prognostic Score (External and Prospective Validation Cohorts)
The previously designed score was applied to all patients in the external and prospective validation cohorts. Cox regression, Kaplan-Meier, and log-rank tests were employed to identify factors impacting OS. Multivariable Cox regression analyses performed in the training cohort were reproduced to validate the impact of the score on OS.
Results
A total of 395 patients were identified and considered for eligibility. Of these, 313 patients with GI-NECs were eligible and included in the final analysis: training cohort (109 patients), external validation cohort (184 patients), and prospective validation cohort (20 patients) (see Figure 1 , CONSORT diagram).
Training Cohort: Patient's Baseline Characteristics, Prognostic Factors, and Design of Prognostic Score
The training cohort included 109 patients; baseline characteristics are summarized in Table 1 . By the end of follow-up, 83.5% of patients had died. The median estimated OS was 11.3 months (95% CI ¼ 8.3 to 14.03 months).
In addition to Ki67 (P ¼ .15) and ECOG-PS (P ¼ .046 for ECOG-PS 2 compared with ECOG-PS 0), which were previously defined as "variables of interest," the following seven variables were found to be prognostic for OS by univariate Cox regression analysis (Supplementary Table 1 , available online): stage (P ¼ .008 for metastatic stage compared with localized stage ), LDH (P < .001), sodium (P ¼ .003), ALP (P < .001), number of metastatic sites (P ¼ .02), presence of liver metastases (P < .001), and presence of lung metastases (P ¼ .03). All these variables were included in the multivariable maximum regression model (Supplementary Table 1 , available online).
Following analysis of 511 potential combinations, the most informative reduced model was selected to design the prognostic score. The selected reduced model included five variables (liver metastases, ECOG-PS, Ki67, LDH, and ALP) (Supplementary Table 1 , available online) and had the following characteristics: AIC of 71.6, AUC of 0.839, and Hosmer-Lemeshow goodness of fit of 0.977. Punctuation for each item was selected, taking into account the hazard ratio from the multivariable analysis of the reduced model (Figure 2 ; Supplementary Table 1, available online). According to the sum of the five items, patients could be assigned a minimum of 0 to a maximum of 6 points. Risk of death increased with each extra point added into the score (Supplementary Figure 1, available online) . Distribution of the prognostic score within TC population is summarized in Supplementary The score was internally validated showing good discrimination (C-Index ¼ 0.76) and calibration (mean error ¼ 0.021, 90th percentile ¼ 0.037) (Figure 3 ).
There was good accuracy for prediction of risk of survival when compared with the maximum regression model. There were no differences between the prognostic score and the maximum regression model at three, six, nine, 12, 18, and 24 months (Supplementary Figure 2, available online) .
Impact of the Score on OS
Multivariable Cox regression analysis, including the score as one of the variables (Table 2) , was performed to assess its impact on survival when adjusted for other variables not included in the score such as sodium (independent prognostic factor identified during the score-building process) (Supplementary Table 1 , available online) and stage (variable of interest). However, lung metastases was another of the independent prognostic factors identified during the score-building process (Supplementary Table 1 , available online); this variable was not included in this multivariable analysis (Table 2 ) because this clinical information was already provided by other variables such as presence of liver metastases (included in the score) and stage (defined as variable of interest and therefore included in multivariable analysis). The score was an independent prognostic factor for OS (HR ¼ 1.86, 95% CI ¼ 1.47 to 2.35, P < .001) when the analysis was adjusted for other variables, such as stage and sodium (Table 2) .
External and Prospective Validation of the Score
One hundred seventy-eight and 20 patients were eligible for inclusion in the external validation and in the prospective validation cohorts, respectively. Baseline characteristics of these validation cohorts are shown in Table 1 . Distribution of the prognostic score within these two populations of patients is summarized in Supplementary Table 2 (available  online) .
The multivariable analysis (including the score as a prognostic variable) performed on the training cohort was replicated with each of the validation cohorts ( Table 2 ). The score remained an independent prognostic factor in both validation cohorts when adjusted for stage and sodium (previously shown to be prognostic variables in the univariate analysis: HR ¼ 1.85, 95% CI ¼ 1.27 to 2.71, P ¼ .001; and HR ¼ 4.51, 95% CI ¼ 1.87 to 10.87, P ¼ .001, for EVC and PVC, respectively).
Deriving the Score in Clinical Practice
The prognostic score has been defined as a discrete variable, with a range from 0 to 6 points. For applicability in clinical practice, the score classified patients into two groups, with statistically significant differences in OS ( (Figure 4 ). When the multivariable analysis was repeated using the score as a dichotomized variable, the score (group A vs B) was an independent prognostic factor in all patient cohorts ( Table 2) . Distribution of the prognostic score as a dichotomized variable within all populations of patients included in this is summarized in Supplementary Table 2 (available online).
Receipt of chemotherapy had an impact on OS in both prognostic groups and was an independent positive prognostic factor (HR for patients receiving chemotherapy ¼ 0.31, 95% CI ¼ 0.20 to 0.48, P < .001) when adjusted for the prognostic score, stage, and sodium in the multivariable analysis. This resulted in the following median OS: 20.7 months for group A treated with chemotherapy (129 patients, 95% CI ¼ 16.7 to 26.4 months), 11.9 months for group A not treated with chemotherapy (24 patients, 95% CI ¼ 4.6 to 81.1 months), 8.1 months for group B treated with chemotherapy (55 patients, 95% CI ¼ 5.4 to 10.8 months), and 2.1 months for group B not treated with chemotherapy (26 patients, 95% CI ¼ 1.4 to 2.4 months).
Discussion
This study represents one of the largest series of patients diagnosed with high-grade NECs to date (6, 12) . High-grade NECs are known to consist of a heterogeneous population (27) in whom prognosis depends on multiple factors (6,12,21) rather than unique variables, hence our interest in developing a prognostic score that would combine the impact of multiple variables (all objective, with the exception of performance status, which is subjective) in one unique measurement. 
ARTICLE
The final GI-NEC score showed prognostic impact, and its ability to identify a patient group with an inferior outcome was validated in an external cohort. This study constitutes a collaborative effort between five European centers with recognized expertise in neuroendocrine malignancies giving credence to the results presented.
The direct application of the GI-NEC score identified two subgroups, a good prognosis (A) and poor prognosis (B) group with marked differences in OS. The magnitude of difference indicates that this score may not only have a role in determining prognosis and aiding treatment discussion between clinicians and patients, but may also influence clinical trial design with respect to patient stratification.
Both prognostic groups benefitted from treatment with systemic chemotherapy. This benefit was more pronounced in group B patients (fourfold OS increase) than in group A patients (twofold OS increase); however, differences due to patient selection bias cannot be excluded. Group B identified cases with behavior similar to small cell lung cancer (SCLC) in terms of prognosis who may derive the greatest benefit from classical platinum plus etoposide chemotherapy combinations.
The identification of two patient cohorts with apparently different clinical courses highlights the need to consider different management strategies between them. For instance, patients classified in group A may be suitable for treatment options beyond platinum-etoposide chemotherapy, including alternative 
chemotherapy combinations for patients with a lower Ki67 or morphologically well-differentiated tumors (6, 12) or locoregionaldirected therapy in cases with liver-predominant disease. In essence, although there is often urgency in starting platinumetoposide chemotherapy in patients with GI-NEC, patients in group A may benefit from case-by-case discussion within a NET multidisciplinary meeting regarding other treatment options. Furthermore, because of the absence of available clinical trials in this setting and the more favorable survival of this particular group, these patients would be well suited for early-phase trials. It is worth mentioning that the most suitable Ki67 cutoff for making clinical management decisions remains unclear. In the Nordic retrospective study, it was suggested that a Ki67 cutoff of 55% was informative for choosing between platinum-based or temozolomide-based treatment (12) . In contrast, the current series identified a different cutoff (80%) as the most informative one with respect to OS (rather than treatment response). These results highlight that it is not advisable to make informed treatment decisions reliant on Ki67 alone. Morphology should also be considered, as suggested by Heetfeld and colleagues (6) .
The group A population still likely constitutes several different subgroups with differing molecular biology. These patients may derive benefit from further characterization (28) . A worldwide collaborative effort to better understand the nature of this pathology should be prioritized by the NET research community.
On the other hand, patients classified in the poor prognosis group, in the absence of other alternatives, may derive the most benefit from therapy traditionally given to patients with SCLC. Our results suggest that in this poor-prognosis subgroup there is an urgent priority to initiate chemotherapy treatment, which may be less pressing in group A patients. This new prognostic tool may become a cornerstone in the stratification of patients for inclusion into clinical trials as a randomization factor, allowing adjustment for multiple prognostic factors at once. This will allow for efficient reduction of stratification variables and may potentially reduce trial sample size and facilitate subgroup analysis. Trial design may also be influenced to develop distinct therapeutic approaches based on the clinical characteristics of both subgroups when evaluating and introducing new therapies. For instance, if we were to design a trial with new immunotherapies (such us anti-PD1-targeted therapy, which has recently shown benefit in Merkel cell carcinoma [29] ), a different approach may be considered in group B patients with induction chemotherapy before introducing the immunotherapy to achieve clinical control of the disease, thus optimizing the use of chemotherapy. However, most patients in group A would not need this sequential approach.
The limitations of this study are the ones that inherently apply to population data that are collected retrospectively (training cohort and external validation cohort), as shown by imbalances identified between patient cohorts (such as primary tumor site, Ki67, and median OS). Despite of the small sample size of the prospective validation cohort, the score retains its prognostic value; however, it would still require confirmation in a longer prospective series, ideally within a clinical trial. In addition, the depth of this analysis is limited to the use of clinical data; that is, chromogranin-A and neurone-specific enolase were not included because of data unavailability. The absence of single central pathology review is attenuated by the documented expertise of these centers and their pathology departments. The fact that patients with no survival data or at least one of the score items missing were excluded from the EVC and PVC could introduce a selection bias. Finally, tumor morphology (well-differentiated high-grade vs poorly differentiated highgrade) was not incorporated into this score because of the nonavailability of this information for the majority of patients. Patients with the emerging entity of NET-G3 are most likely to be included in group A; the high Ki67 cutoff employed in this study (80%) may negate this limitation because of the low rate of patients with well-differentiated morphology who would be expected to have a Ki67 higher than 80% (6) .
In summary, in this study, the GI-NEC score was designed and validated for patients with GI-NECs for prognostication of OS as a tool to aid clinician selection of patients for treatment or clinical trial inclusion. This score could also be incorporated as a stratification factor in future comparative trials to assist adjustment for prognostic factors and secure comparability between arms.
